论文部分内容阅读
前言 以前糖尿病的治療大多依靠胰島素注射,但該類制劑乃系蛋白荷爾蒙物質,應用後往往可引起過敏症等付作用,且限于注射,其不便可知,近年雖有P607,Tolbutamido B 860,Co butamideB z55,DB1,等口服糖尿病制劑,但該類葯物都具有一定的付作用,如胃腸障碍等等。據報道中草酸監類於動物實驗,對因注射四氧嘧而引起的糖尿及臨床應用於糖尿病患者,亦具有降低血糖作用,(1、2、3、)且連續應用於鼠、狗、兔等實驗内服超過一年,在肝、脾、腎內也不發生病變(5)。Yoshiro,kolaysli等應用於人,最大劑量,每日
Introduction Most of the previous treatment of diabetes rely on insulin injection, but such preparations are Department of protein hormone material, the application can often lead to allergies and other pay, and limited to injection, the inconvenience shows that in recent years, although P607, Tolbutamido B 860, Co butamideB z55, DB1, and other oral diabetes preparations, but these drugs have a certain pay role, such as gastrointestinal disorders and so on. It has been reported that oxalic acid supercritical animal experiments, due to the injection of alloxan caused diabetes and clinical application in patients with diabetes, also has a lower blood sugar, (1,2,3,) and continuous application in mice, dogs, rabbits Oral and other experiments for more than a year, in the liver, spleen, kidney disease does not occur (5). Yoshiro, kolaysli, etc. applied to humans, the maximum dose, daily